FANJ
EPZM

Financial Architects (New Jersey)’s Epizyme, Inc EPZM Stock Holding History

Financial Architects (New Jersey)’s Portfolio EPZM Stock Details EPZM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-2,500
Closed -$38K – 1643
2017
Q2 		$38K Hold
2,500
– – 0.01% 769
2017
Q1 		$43K Hold
2,500
– – 0.01% 710
2016
Q4 		$30K Hold
2,500
– – 0.01% 723
2016
Q3 		$25K Hold
2,500
– – 0.01% 792
2016
Q2 		$26K Hold
2,500
– – 0.01% 720
2016
Q1 		$30K Buy
+2,500
New +$25.3K 0.01% 499

Other funds holding EPZM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Financial Architects (New Jersey)'s EPZM Position: Q3 2017 in Review

Financial Architects (New Jersey) sold out of Epizyme, Inc (EPZM) in Q3 2017, closing a stake of 2,500 shares — an estimated $38K sold.

Financial Architects (New Jersey) first reported a position in EPZM in Q1 2016 and held it in 6 quarters. The position peaked at $43K in Q1 2017. 104 funds tracked by Wall St. Rank hold EPZM as of Q3 2017.

  • Financial Architects (New Jersey) reported no remaining Epizyme, Inc position as of Q3 2017 after selling out during the quarter.
  • Financial Architects (New Jersey) sold 2,500 Epizyme, Inc shares in Q3 2017, an estimated $38K.
  • Financial Architects (New Jersey) first reported a position in Epizyme, Inc in Q1 2016 and held it in 6 quarters.
  • Financial Architects (New Jersey)'s Epizyme, Inc position peaked at $43K in Q1 2017.
  • 104 funds tracked by Wall St. Rank held Epizyme, Inc as of Q3 2017.

Based on Financial Architects (New Jersey)'s 13F filing for Q3 2017, filed 23 Oct 2017.